Showing results (91-100 of 283) with videos related to
Sort By:
Pageof 29
Biological Psychiatry|August 1, 1990
Sleep polygraphy in schizophrenia: methodological issuesG K Thaker, A M Wagman, C A TammingaInternational Clinical Psychopharmacology|August 5, 1998
The role of negative symptoms and cognitive dysfunction in schizophrenia outcomeC A Tamminga, R W Buchanan, J M GoldNeuroscience Research|April 4, 1998
Neurochemical and metabolic consequences of elevated cerebrospinal fluid quinolinic acid concentrations in rat brainK Maeda, H Kaneda, W O Whetsell, et al.Neuroscience Letters|March 15, 1985
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptorsL Steardo, M Knight, C A Tamminga, et al.Synapse (New York, N.Y.)|February 17, 2001
Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathwaysK Sakai, X M Gao, T Hashimoto, et al.European Journal of Pharmacology|September 7, 1993
Delayed regional metabolic actions of phencyclidineX M Gao, O Shirakawa, F Du, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|November 24, 1998
Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophreniaA C Lahti, M Weiler, A Carlsson, et al.Endocrinology|July 1, 1987
Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptideK Tanimoto, C A Tamminga, T N Chase, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 1, 1995
Subanesthetic doses of ketamine stimulate psychosis in schizophreniaA C Lahti, B Koffel, D LaPorte, et al.Schizophrenia Bulletin|January 1, 1995
Prodromal symptoms vs. early warning signs and clinical action in schizophreniaJ Bustillo, R W Buchanan, W T CarpenterPageof 29